TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has issued an announcement.
Botanix Pharmaceuticals announced the results of its 2025 Annual General Meeting, where all resolutions were passed except for the approval of the Remuneration Report. The meeting included the re-election of directors and the ratification of placement shares issued to investors, indicating continued support from shareholders and strategic positioning in the market.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, specializing in innovative treatments for skin conditions. The company has received FDA approval for its lead product, Sofdra, which is the first new chemical entity approved for the treatment of primary axillary hyperhidrosis, offering a novel solution for patients with limited treatment options.
Average Trading Volume: 7,431,045
Technical Sentiment Signal: Sell
Current Market Cap: A$256.2M
See more data about BOT stock on TipRanks’ Stock Analysis page.